One could argue that it already has. One drug is enough, one patient is enough.

We’re just getting started.

This edit will always live rent free in my head

Not something I can answer directly. I assume it’s a time thing, easier to funnel time/energy to the larger mega-round companies we’re seeing more of in biotech?

1 is slow, 2 would be quick.

1 - Make this an expectation in time. Seed/accelerators (eg Nucleate) start the push. The best firms start to do this, and it becomes something to expect.

2 - Create leverage. Companies provide specific metrics or other essential info in exchange for deep feedback

Yeah completely it would be.

To your original point, it comes down to how this gets incentivized. One thing I’ve seen is a founder aggressively coming back and asking for feedback and/or reasoning for a negative decision. So one aspect of this can be to empower founders to do this.

I would worry that a lot of the passes are because they don’t understand, or believe in the differentiation. That’s a tough message to pass on without significant context?

Macrophages have a lot of innate pathways to shut down expression from exogenous places. Anecdotally, I’ve seen the same issue of a transduction with no expression on RAW264 cells, but there are ways to design around it: pmc.ncbi.nlm.nih.gov/articles/PMC...

Caribou Biosciences - Jan 2011
Editas Medicine - November 2013
Intellia Therapeutics - November 2014

1.0x too, you’re a monster

Awesome news Aron, congratulations!!

CNN claiming it may have been targeted

Completely agree on method-dependence here too, especially in HSC populations where DNA repair kinetics will vary greatly throughout the process.